SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

Excerpt from the Press Release:

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.  

SOPHiA DDM™ Digital Twins uses each patient’s unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease. Oncologists can use the virtual replica of the patient, or Digital Twin, to simulate treatment responses, disease trajectories, and survival outcomes in real time, and to explore potential treatment strategies virtually before making decisions at the bedside.

“Digital twin technology enables integrative visualization of multimodal oncologic data, revealing latent correlations across modalities. By simulating disease trajectories and therapeutic responses within a virtual environment, Digital Twins offer a framework for in silico experimentation, supporting anticipatory and individualized clinical decision-making,” said Dr. Pierre Heudel, Medical Oncologist, Centre Léon Bérard.

“This breakthrough technology represents an important step forward in helping clinicians make more informed decisions for complex cancers,” said Dr. Clara Montagut, Head of Gastrointestinal Cancer, Hospital del Mar. “Having a digital model that can simulate potential outcomes before treatment has the potential to be transformative in how we deliver future care.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release